reason report
bottom line lower ep estim
accur reflect impact bottom line
divestitur portion patient monitor recoveri busi
mp complet prior estim
reflect misinterpret manag ep growth
guidanc prior estim appli growth
pre-divestitur ep new ep estim
move vs consensu impli
y/i oper growth rate ex fx divestitur bring
ep estim lower cent
vs consensu ep estim remain
unchang posit impact divestitur top-lin
growth better contempl estim
remain sidelin pend clariti fundament competit
cycl headwind competit mri-saf product launch
on-going competit pressur spinal cord stimul
addit see increment margin expans tough come
given top-lin dynam
price-to-earnings multipl ep estim assum
share sustain current multipl now-low
ep estim though believ could eventu
return path consist mid-single-digit top-lin growth time
less certain see limit multipl expans
mid-single-digit growth trajectori larg predic
recent upcom new product launch sustain trend
without risk
medic suppli devic
ep
net debt total capit
price-to-earnings lt ep growth
compani inform leerink partner llc research
revenu mm ep
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rate share market perform price target believ
return mid-single-digit top-lin growth trajectori eventu nearli total
sale cardiac rhythm manag spine market estim grow
low-single-digit best mdt sustain growth trajectori larg predic
recent upcom new product launch well success integr covidien
largest acquisit compani histori
ceo omar ishrak helm clearli focus control cost help off-set
on-going price pressur slow market growth broadli med-tech excis tax
name see opportun margin expans combin compani
attempt extract signific cost synergi though compani continu make progress
time extent margin improv still remain challeng increas fx pressur
compani goal reach cost synergi remain aggress despit
made meaning progress toward goal
despit earli sign market stabil market growth recoveri coupl
continu soft spine inclin remain sidelin share
pend clariti execut upcom new product launch help stem
market share loss spine drive market share gain busi
success deliv increment margin expans beyond cov synergi
major med-tech market broadli spine specif experienc real
share current trade ep modestli high-teen
multipl rang broader large-cap med-tech univers though
believ could eventu return path consist mid-single-digit top-lin
growth time less certain see limit multipl expans
mid-single-digit growth trajectori larg predic recent upcom new product
launch sustain trend without risk price target
appli basic stabl multipl ep estim
risk valuat includ continu signific spine market spine sale declin
market fail regain momentum greater-than-expect drug elut stent de market
share loss greater infus sale declin failur deliv product pipelin failur
success execut cost save initi
dollar million except per share data
good sold
research develop expens
pre-tax incom continu oper
net incom continu oper
earn discontinu oper net
net incom attribut non-controlling interest
net incom attribut
sg sale
 sale
oper expens sale
compani report leerink partner estim
